Table 1 Characteristics and treatments of patients receiving rituximab
Baseline Characteristics (N = 177) | |
|---|---|
Age (years) at first rituximab | 47 (13–82) |
Male sex | 54 (31%) |
Diagnosis | 100 (56%) |
  Primary Systemic Vasculitis | 75 (42%) |
  Granulomatosis with polyangiitis (Wegener’s) | 15 (8%) |
  Microscopic Polyangiitis | 10 (6%) |
  Churg Strauss Syndrome | 43 (24%) |
  Systemic lupus erythematosus | 3 (2%) |
  Behcet’s disease | 3 (2%) |
  Henoch Schonlein Purpura | 28 (16%) |
  Other# |  |
Prior disease duration (months) | 52 (0–396) |
Prior cyclophosphamide (N = 176) | 121 (69%) |
Cumulative cyclophosphamide (g) (N = 171) | 8 (0–163) |
Prior therapies (N = 176) |  |
  Mycophenolate Mofetil | 123 (70%) |
  Azathioprine | 107 (61%) |
  Methotrexate | 46 (26%) |
  Intravenous immunoglobulin | 40 (23%) |
  Hydroxychloroquine | 29 (16%) |
  Anti-tumor necrosis factors agents | 26 (15%) |
  Plasma exchange | 26 (15%) |
  Alemtuzumab | 20 (11%) |
  Other IS/IM$ | 63 (36%) |
Number of prior IS/IM agents (excluding steroids) (N = 176) | 3 (0–14) |
Patient characteristics at first rituximab infusion | |
Indication | Â |
  Active disease | 127 (72%) |
  Consolidation of remission | 50 (28%) |
Relapsing/refractory disease | 170 (96%) |
New disease | 7 (4%) |
Follow-up (months) | 43 (2–100) |
Cyclophosphamide at time of rituximab | 42 (24%) |
Rituximab total dose | Â |
  Total dose (g) (N = 177) | 6 (1–20.2) |
  Dose/BSA (g/m2) (N = 149) | 3.3 (0.8-10.4) |
  Dose/BSA/year (g/m2/year) (N = 149) | 1.1 (0.1-3.2) |